Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Current Leases (2021 - 2026)

Elicio Therapeutics filings provide 3 years of Current Leases readings, the most recent being $910000.0 for Q4 2023.

  • On a quarterly basis, Current Leases rose 31.5% to $910000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $910000.0, a 31.5% increase, with the full-year FY2023 number at $910000.0, up 31.5% from a year prior.
  • Current Leases hit $910000.0 in Q4 2023 for Elicio Therapeutics, down from $938000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $985000.0 in Q2 2023 to a low of $60000.0 in Q1 2022.
  • Median Current Leases over the past 3 years was $858500.0 (2021), compared with a mean of $686083.3.
  • Biggest five-year swings in Current Leases: plummeted 92.68% in 2022 and later skyrocketed 1488.71% in 2023.
  • Elicio Therapeutics' Current Leases stood at $894000.0 in 2021, then decreased by 22.6% to $692000.0 in 2022, then surged by 31.5% to $910000.0 in 2023.
  • The last three reported values for Current Leases were $910000.0 (Q4 2023), $938000.0 (Q3 2023), and $985000.0 (Q2 2023) per Business Quant data.